Sign In
Buy NVAX
$10.20
-0.0100 (-0.0979%)
At Close: Jun 03, 2026
Novavax, Inc. (NVAX) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
07:00pm, Thursday, 14'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violatio
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
06:45pm, Thursday, 14'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advise
NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.
07:25am, Thursday, 14'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violatio
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
09:16am, Wednesday, 13'th Nov 2024
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.
Novavax to Participate in Jefferies London Healthcare Conference
08:00am, Wednesday, 13'th Nov 2024
GAITHERSBURG, Md. , Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participat
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
07:30am, Wednesday, 13'th Nov 2024
Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial c
NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.
05:30pm, Tuesday, 12'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violatio
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
05:15pm, Tuesday, 12'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advise
Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript
11:52am, Tuesday, 12'th Nov 2024
Novavax, Inc. (NASDAQ:NVAX ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Execut
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
11:01am, Tuesday, 12'th Nov 2024
Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax's stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
10:29am, Tuesday, 12'th Nov 2024
Novavax Inc.'s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue.
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
10:21am, Tuesday, 12'th Nov 2024
Novavax (NVAX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.26 per share a year ago.
Novavax Stock Dives Even Though Results Beat Forecasts
09:44am, Tuesday, 12'th Nov 2024
The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared with the $74 million analysts expected.
Lost Money on Novavax, Inc. (NVAX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
08:15am, Tuesday, 12'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violatio
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
08:06am, Tuesday, 12'th Nov 2024
Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to Sanofi.
